A newly published study of a molecular diagnostic test by Myriad Genetics has demonstrated that the test can accurately predict which men will develop biochemical recurrence or metastatic disease following radical prostate surgery.
Read MoreFDA has granted premarket notification (510(k)) clearance for the CytoScan Dx assay, a new test intended for the postnatal detection of DNA copy-number variants in patients referred for chromosomal testing.
Read MoreA pilot program in clinical genomics will allow a small group of patients at Stanford Hospital and Clinics and Lucile Packard Children’s Hospital Stanford to have their DNA deciphered to help doctors with diagnosis and treatment.
Read More
New products include the Cytation 3 cell imaging multi-mode reader by BioTek and the myPlan Lung Cancer test from Myriad.
Read More
Qiagen NV and Exosome Diagnostics Inc. have expanded their existing strategic partnership to develop a first-in-class, noninvasive molecular diagnostic for use in detecting and monitoring actionable genetic mutations in lung cancer patients.
Read More